Researchers Describe Aggressive Breast Cancer Molecular Mechanism
|
By LabMedica International staff writers Posted on 11 Nov 2016 |

Image: The structural model of the SIRT2 protein (Photo courtesy of Wikimedia Commons).
Cancer researchers have found that SIRT2, a member of the sirtuin family of enzymes, stabilizes Slug, a transcription factor that promotes the development, growth, and spread of basal-like breast cancer.
Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown.
To better understand the link between Slug and BLBC, investigators at Tufts University School of Medicine (Boston, MA, USA) screened BLBC cultures for factors that would stabilize Slug activity.
They reported in the October 25, 2016, online edition of the journal Cell Reports that Slug underwent acetylation-dependent protein degradation and identified the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilized Slug, whereas SIRT2 overexpression extended Slug stability. SIRT2 deacetylated Slug protein at lysine residue K116 to prevent Slug degradation.
SIRT2 was frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reversed Slug stabilization, caused the loss of clinically relevant pathological features of BLBC, and inhibited tumor growth. Without SIRT2, tumor cells had a more than 60% reduction in invasive capacity compared to normal basal-like tumor cells. SIRT2-depleted cells also had significantly decreased capacity for growth and self-renewal. This diminished malignancy could be reversed by artificially introducing Slug protein back into cells.
"Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form. By targeting a master transcription factor regulator in basal-like cells, we were able to reduce malignant behaviors," said senior author Dr. Charlotte Kuperwasser, professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. "Our findings now provide a molecular rationale for new approaches to help improve the poor clinical outcomes currently associated with these cancers."
"Cancer cells find sophisticated ways to regulate essential proteins they need for their survival and growth. The transcriptional factor Slug is one such protein and is often tightly regulated in both normal and cancer cells. While we have found that SIRT2 plays an important role in prolonging Slug expression, it is too soon to know whether targeting SIRT2 will be sufficient to abolish Slug entirely in cancer cells and therefore lead to tumor regression," said Dr. Kuperwasser. "A significant amount of work remains to be done before we can verify if targeting SIRT2 can be an Achilles' heel for treating basal-like breast cancers."
Related Links:
Tufts University School of Medicine
Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown.
To better understand the link between Slug and BLBC, investigators at Tufts University School of Medicine (Boston, MA, USA) screened BLBC cultures for factors that would stabilize Slug activity.
They reported in the October 25, 2016, online edition of the journal Cell Reports that Slug underwent acetylation-dependent protein degradation and identified the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilized Slug, whereas SIRT2 overexpression extended Slug stability. SIRT2 deacetylated Slug protein at lysine residue K116 to prevent Slug degradation.
SIRT2 was frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reversed Slug stabilization, caused the loss of clinically relevant pathological features of BLBC, and inhibited tumor growth. Without SIRT2, tumor cells had a more than 60% reduction in invasive capacity compared to normal basal-like tumor cells. SIRT2-depleted cells also had significantly decreased capacity for growth and self-renewal. This diminished malignancy could be reversed by artificially introducing Slug protein back into cells.
"Breast cancer is not one disease, and of the several distinct subtypes, basal-like breast cancer represents the most aggressive form. By targeting a master transcription factor regulator in basal-like cells, we were able to reduce malignant behaviors," said senior author Dr. Charlotte Kuperwasser, professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. "Our findings now provide a molecular rationale for new approaches to help improve the poor clinical outcomes currently associated with these cancers."
"Cancer cells find sophisticated ways to regulate essential proteins they need for their survival and growth. The transcriptional factor Slug is one such protein and is often tightly regulated in both normal and cancer cells. While we have found that SIRT2 plays an important role in prolonging Slug expression, it is too soon to know whether targeting SIRT2 will be sufficient to abolish Slug entirely in cancer cells and therefore lead to tumor regression," said Dr. Kuperwasser. "A significant amount of work remains to be done before we can verify if targeting SIRT2 can be an Achilles' heel for treating basal-like breast cancers."
Related Links:
Tufts University School of Medicine
Latest BioResearch News
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
Channels
Clinical Chemistry
view channel
Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
Kidney transplantation remains constrained by organ scarcity and uncertainty about the quality of deceased-donor kidneys. In the United States, more than 92,000 people are awaiting a kidney transplant,... Read more
Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read moreMolecular Diagnostics
view channel
New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
Many liquid biopsy strategies for monitoring breast cancer recurrence focus on detecting genetic mutations in tumor DNA. Researchers are evaluating whether additional features of circulating cell-free... Read more
Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
Breast cancer screening continues to face challenges, including limited detection of small tumors and uneven participation, particularly among women with dense breasts. These limitations can leave diagnostic... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
Global Urinalysis Market Gowth Driven by Demand for Automated and POC Testing
Urinalysis is a widely used diagnostic method for detecting urinary tract infections, kidney and liver diseases, diabetes, and other conditions through urine sample analysis. These tests support early... Read more







